Read + Share
Weickhardt AJ, Lau DK, Hodgson-Garms M, Lavis A, et al. Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in
FGFR3 fusion-driven bladder cancer. BMC Cancer 2022;22:478.
PMID: 35501832
|
 |
|
Weickhardt AJ, Lau DK, Hodgson-Garms M, Lavis A, et al. Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in
FGFR3 fusion-driven bladder cancer. BMC Cancer 2022;22:478.
PMID: 35501832
|
|
|
|